- Home
- TFII vs RYTM Comparison
TFII vs RYTM Comparison
Compare TFII & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFII
- RYTM
- Stock Information
- Founded
- TFII 1957
- RYTM 2008
- Country
- TFII Canada
- RYTM United States
- Employees
- TFII N/A
- RYTM N/A
- Industry
- TFII Trucking Freight/Courier Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- TFII Industrials
- RYTM Health Care
- Exchange
- TFII Nasdaq
- RYTM Nasdaq
- Market Cap
- TFII 7.4B
- RYTM 6.4B
- IPO Year
- TFII N/A
- RYTM 2017
- Fundamental
- Price
- TFII $90.78
- RYTM $111.36
- Analyst Decision
- TFII Buy
- RYTM Strong Buy
- Analyst Count
- TFII 11
- RYTM 13
- Target Price
- TFII $120.27
- RYTM $110.38
- AVG Volume (30 Days)
- TFII 244.4K
- RYTM 532.3K
- Earning Date
- TFII 10-30-2025
- RYTM 11-04-2025
- Dividend Yield
- TFII 1.98%
- RYTM N/A
- EPS Growth
- TFII N/A
- RYTM N/A
- EPS
- TFII 4.34
- RYTM N/A
- Revenue
- TFII $8,263,477,999.00
- RYTM $156,287,000.00
- Revenue This Year
- TFII N/A
- RYTM $46.14
- Revenue Next Year
- TFII $4.15
- RYTM $63.37
- P/E Ratio
- TFII $20.42
- RYTM N/A
- Revenue Growth
- TFII 3.10
- RYTM 53.55
- 52 Week Low
- TFII $72.02
- RYTM $45.91
- 52 Week High
- TFII $155.12
- RYTM $113.91
- Technical
- Relative Strength Index (RSI)
- TFII 47.62
- RYTM 65.17
- Support Level
- TFII $88.31
- RYTM $105.40
- Resistance Level
- TFII $97.75
- RYTM $111.03
- Average True Range (ATR)
- TFII 3.31
- RYTM 4.04
- MACD
- TFII 0.04
- RYTM 0.49
- Stochastic Oscillator
- TFII 37.88
- RYTM 84.00
About TFII TFI International Inc.
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customers' specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.